Diversified Biomedical Innovation Company Focused on Developing High Impact, High Value, Evidence-Based Therapeutic Solutions

Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Our main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization.

Orchestra BioMed’s business strategy is to leverage partnerships with established global market leaders to optimize the clinical impact and commercial value of its products. Orchestra BioMed expects to generate long-term, high margin cash flow from royalties, revenue sharing, as well as licensing and development payments from strategic partners that secure commercial rights to Orchestra BioMed-developed products. Orchestra BioMed’s core innovation and development expertise is in the areas of drug delivery, interventional devices, bioelectronics and neuromodulation.

The Company’s lead cardiovascular therapies, which were developed from concept stage by Orchestra BioMed’s wholly-owned subsidiaries, are highly proprietary and have demonstrated promising clinical results in addressing specific high-need patient populations with artery disease and hypertension.

  • Virtue® Sirolimus-Eluting Balloon (SEB) is a novel, first in-class device that delivers delayed-release bioabsorbable particle encapsulated Sirolimus, the proven gold-standard drug for preventing restenosis of treated arteries, to the vessel wall during balloon angioplasty without the need for a permanent implant.

  • BackBeat® Cardiac Neuromodulation Therapy (CNT) is a patented implantable cardiac stimulation-based treatment for hypertension that immediately and substantially lowers blood pressure while simultaneously modulating autonomic nervous system responses that normally drive and maintain blood pressure higher.

Orchestra BioMed also has significant strategic ownership in other therapeutic device companies that were originally founded, financed and developed with the assistance from the principals of Orchestra BioMed. These include one wholly-owned subsidiary (FreeHold Surgical®) and two large minority interests in other therapeutic device companies (Motus GI®, Vivasure® Medical.)

Freehold Surgical
Vivasure Medical
Motus GI
Have any questions?
Contact us at 917.254.4900 or info@orchestrabiomed.com